Detailed Information on Publication Record
2023
Synthesis and evaluation of biological activity of newly designed hydroxamates as potential HDAC inhibitors
ONUŠČÁKOVÁ, Magdaléna, Hana PÍŽOVÁ, Tereza KAUEROVÁ, Peter KOLLÁR, Pavel BOBÁĽ et. al.Basic information
Original name
Synthesis and evaluation of biological activity of newly designed hydroxamates as potential HDAC inhibitors
Name in Czech
Syntéza a hodnocení biologické aktivity nově navržených hydroxamátů jako potenciálních inhibitorů HDAC
Authors
ONUŠČÁKOVÁ, Magdaléna (703 Slovakia, belonging to the institution), Hana PÍŽOVÁ (203 Czech Republic, belonging to the institution), Tereza KAUEROVÁ (203 Czech Republic, belonging to the institution), Peter KOLLÁR (203 Czech Republic, belonging to the institution) and Pavel BOBÁĽ (703 Slovakia, belonging to the institution)
Edition
57th Conference: Advances in Organic, Bioorganic and Pharmaceutical Chemistry – Liblice. 2023
Other information
Language
English
Type of outcome
Prezentace na konferencích
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14160/23:00133253
Organization unit
Faculty of Pharmacy
Keywords in English
HDAC inhibitors; Hydroxamic acids; Antineoplastic activity
Změněno: 5/4/2024 07:31, Mgr. Daniela Černá
Abstract
V originále
Histone deacetylases (HDACs) are metalloenzymes involved in the regulation of fundamental cellular processes, such as cell cycle progression, differentiation, and tumorigenesis. The abnormal function of HDACs can induce severe human diseases, including cancer, pulmonary disease, and neurodegenerative disorders.1 Histone deacetylase inhibitors (HDACi) represent a relatively new generation of drugs with the ability to affect the expression of specific genes, which can repair controlled proliferation or damage apoptotic processes in tumor cells
Links
EF19_073/0016943, research and development project |
| ||
MUNI/IGA/1339/2021, interní kód MU |
|